Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) – Equities researchers at Leerink Partnrs issued their FY2027 earnings estimates for shares of Blueprint Medicines in a research report issued to clients and investors on Tuesday, January 14th. Leerink Partnrs analyst A. Berens forecasts that the biotechnology company will post earnings per share of $4.98 for the year. The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.68) per share.
Several other analysts have also recently commented on BPMC. HC Wainwright reiterated a “buy” rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, November 15th. UBS Group started coverage on Blueprint Medicines in a research note on Thursday, October 24th. They issued a “neutral” rating and a $88.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $124.00 target price (down previously from $135.00) on shares of Blueprint Medicines in a research note on Monday. Needham & Company LLC reissued a “buy” rating and issued a $135.00 price target on shares of Blueprint Medicines in a research note on Monday. Finally, Guggenheim reaffirmed a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $122.72.
Blueprint Medicines Stock Performance
NASDAQ BPMC opened at $103.95 on Thursday. The company has a market capitalization of $6.60 billion, a price-to-earnings ratio of -49.27 and a beta of 0.61. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. Blueprint Medicines has a twelve month low of $72.24 and a twelve month high of $121.90. The stock has a fifty day simple moving average of $93.85 and a 200 day simple moving average of $95.36.
Blueprint Medicines (NASDAQ:BPMC – Get Free Report) last announced its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.97) by $0.08. The firm had revenue of $128.20 million during the quarter, compared to analysts’ expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The company’s revenue was up 126.5% on a year-over-year basis. During the same period in the prior year, the company posted ($2.20) EPS.
Institutional Investors Weigh In On Blueprint Medicines
A number of hedge funds have recently modified their holdings of the stock. Empirical Asset Management LLC purchased a new stake in Blueprint Medicines in the fourth quarter worth $2,348,000. Exome Asset Management LLC bought a new position in shares of Blueprint Medicines during the 3rd quarter worth $3,395,000. Franklin Resources Inc. grew its stake in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock worth $3,259,000 after acquiring an additional 265 shares during the period. Synovus Financial Corp increased its holdings in Blueprint Medicines by 4.0% in the 3rd quarter. Synovus Financial Corp now owns 24,047 shares of the biotechnology company’s stock worth $2,224,000 after acquiring an additional 922 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in Blueprint Medicines in the 3rd quarter valued at about $202,000.
Insiders Place Their Bets
In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total value of $216,257.40. Following the transaction, the chief operating officer now directly owns 71,657 shares in the company, valued at $6,814,580.70. The trade was a 3.08 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $102.28, for a total transaction of $511,400.00. Following the transaction, the director now directly owns 157,557 shares of the company’s stock, valued at $16,114,929.96. This represents a 3.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 30,970 shares of company stock valued at $2,914,246 in the last 90 days. 4.21% of the stock is currently owned by corporate insiders.
About Blueprint Medicines
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Recommended Stories
- Five stocks we like better than Blueprint Medicines
- 3 Warren Buffett Stocks to Buy Now
- Cerence AI: One-Hit Wonder or Long-Term Winner After NVIDIA Pact?
- Upcoming IPO Stock Lockup Period, Explained
- UnitedHealth Group Pulls Back Into Another Healthy Opportunity
- What is the Nikkei 225 index?
- Micron Technology: Riding the AI Wave to Long-Term Growth
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.